0000950170-24-030817.txt : 20240313 0000950170-24-030817.hdr.sgml : 20240313 20240313163110 ACCESSION NUMBER: 0000950170-24-030817 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240312 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240313 DATE AS OF CHANGE: 20240313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pyxis Oncology, Inc. CENTRAL INDEX KEY: 0001782223 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831160910 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40881 FILM NUMBER: 24746380 BUSINESS ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: (617) 221-9059 MAIL ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 8-K 1 pyxs-20240312.htm 8-K 8-K
0001782223false00017822232024-03-122024-03-12

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 12, 2024

 

 

Pyxis Oncology, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40881

83-1160910

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

321 Harrison Avenue

 

Boston, Massachusetts

 

02118

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 617-221-9059

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

PYXS

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Director

On March 12, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Santhosh Palani, Ph.D., CFA® , to its Board of Directors (the “Board”). The Board has determined that Dr. Palani qualifies as an independent director under the corporate governance standards of The Nasdaq Stock Market and the applicable rules adopted by the U.S. Securities and Exchange Commission (the “SEC”). There are no arrangements or understandings between Dr. Palani and any other person pursuant to which Dr. Palani is to be appointed as a director. Dr. Palani has no family relationships with any of the Company's directors or executive officers.

Since the beginning of the last fiscal year, there have been no related party transactions between the Company and Dr. Palani that would be reportable under Item 404(a) of Regulation S-K.

Dr. Palani has not yet been appointed to any committees of the Board.

Dr. Palani will be eligible for compensation under the Company’s director compensation plan, as described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 28, 2023. The Board also granted Dr. Palani stock options to purchase 69,760 shares of common stock with an exercise price of $5.70 per share. These stock options vest in three equal annual installments, subject to Dr. Palani’s continued service through the applicable vesting date.

Indemnification Agreement

In connection with his appointment to the Board, Dr. Palani entered into an indemnification agreement in the same form as executed by the other members of the Board and attached to the Company's Form 10-K for the year ended December 31, 2022, filed with the SEC on March 22, 2023.

Item 7.01 Regulation FD Disclosure.

On March 13, 2024, the Company issued a press release announcing the appointment of Dr. Palani to the Board. The full text of the press release issued in connection with this announcement is furnished herewith as Exhibit 99.1.

The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company's filings with the SEC, regardless of any general incorporation language in such filings, except to the extent expressly set forth by reference in such filing.

Item 9.01 Financial Statements and Exhibits.

 (d) Exhibits

 Exhibit No.

Description

99.1

Press Release dated March 13, 2024

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Pyxis Oncology, Inc.

 

 

 

 

Date:

March 13, 2024

By:

/s/ Pamela Connealy

 

 

 

Pamela Connealy
Chief Financial Officer and Chief Operating Officer
 

 

 

 EX-99.1 2 pyxs-ex99_1.htm EX-99.1 EX-99.1

 

 

Exhibit 99.1

img244827169_0.jpg 

 

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

March 13, 2024

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.

“We are thrilled to have Santhosh join the Pyxis Oncology board. Santhosh brings a wealth of business, investment, strategic, and board experience to our team,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. “Santhosh’s guidance, drawing from his experience working across the biopharma industry, will be invaluable as we continue clinical development of our lead asset, PYX-201, a first-in-class and first-in-concept tumor stroma targeting ADC against EDB-fibronectin. His background is highly complementary with those of our other Board members, and I look forward to beginning our work together to drive Pyxis Oncology’s future growth.”

Dr. Palani is a seasoned leader and entrepreneur with over a decade of strategic expertise and drug development experience in the biotechnology and pharmaceutical industries. Dr. Palani is a former investment partner and a current advisory partner at PFM Health Sciences, a leading healthcare investment advisory firm. Prior to joining PFM, Dr. Palani was a Principal at New Enterprise Associates (NEA). Prior to NEA, he was a Vice President of Biotechnology Equity Research at Cowen and Company. Dr. Palani began his career in oncology drug development at Pfizer Inc. and Takeda Pharmaceuticals. He received his Ph.D. in bioengineering from the University of Pennsylvania and completed his postdoctoral work in biochemistry and molecular biophysics at Columbia University. He also holds an M.S. in chemical engineering from Texas A&M University and a B.S. in chemical engineering from the University of Madras, India. Dr. Palani is a CFA® Charterholder.

“I am delighted to join the Board of Directors at Pyxis Oncology at such a pivotal moment in the Company's journey as they anticipate data readouts for their lead ADC program, PYX-201, and their IO program, PYX-106, in 2024,” said Dr. Santhosh Palani. “I look forward to collaborating with Lara, the board, and the leadership team to advance a promising pipeline that could impact patients and deliver value to our shareholders.”

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for mono and combination therapies. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care. To learn more, visit www.pyxisoncology.com or follow us on Twitter and LinkedIn.

Forward Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to be,” “will,” “would,” or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled “Risk Factors” set forth in Pyxis Oncology’s Annual Report on Form 10-K for the year ended December 31, 2022, Pyxis Oncology’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, Pyxis Oncology’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, Pyxis Oncology’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and our other filings, each of which is on file with the Securities and Exchange Commission. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements

Pyxis Oncology Contact

Pamela Connealy

CFO and COO

ir@pyxisoncology.com

1

 GRAPHIC 3 img244827169_0.jpg GRAPHIC begin 644 img244827169_0.jpg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end EX-101.SCH 4 pyxs-20240312.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information
Mar. 12, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 12, 2024
Entity Registrant Name Pyxis Oncology, Inc.
Entity Central Index Key 0001782223
Entity Emerging Growth Company true
Entity File Number 001-40881
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 83-1160910
Entity Address, Address Line One 321 Harrison Avenue
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02118
City Area Code 617-
Local Phone Number 221-9059
Entity Information, Former Legal or Registered Name
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol PYXS
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports pyxs-20240312.htm pyxs-20240312.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "pyxs-20240312.htm": { "nsprefix": "pyxs", "nsuri": "http://pyxisoncology.com/20240312", "dts": { "inline": { "local": [ "pyxs-20240312.htm" ] }, "schema": { "local": [ "pyxs-20240312.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_1125563f-e6ea-41e0-90f0-ad577ca137bf", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "pyxs-20240312.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_1125563f-e6ea-41e0-90f0-ad577ca137bf", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "pyxs-20240312.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationFormerLegalOrRegisteredName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationFormerLegalOrRegisteredName", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Information, Former Legal or Registered Name", "documentation": "Former Legal or Registered Name of an entity" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://pyxisoncology.com/20240312/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950170-24-030817-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-030817-xbrl.zip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end XML 15 pyxs-20240312_htm.xml IDEA: XBRL DOCUMENT 0001782223 2024-03-12 2024-03-12 0001782223 false 8-K 2024-03-12 Pyxis Oncology, Inc. DE 001-40881 83-1160910 321 Harrison Avenue Boston MA 02118 617- 221-9059 false false false false Common Stock, par value $0.001 per share PYXS NASDAQ true true